Alteogen announced on March 17 that it has signed an exclusive global license agreement with MedImmune, AstraZeneca’s biologics subsidiary, to develop and commercialize subcutaneous (SC) oncology drugs using its proprietary human hyaluronidase technology, ALT‑B4.

Under the agreement, Alteogen will receive a $25 million upfront payment and is eligible for up to $725 million in clinical and regulatory milestone payments, plus tiered royalties on net sales. The upfront payment is due by April 16, within 30 days of the deal’s effective date.

ALT‑B4 enhances tissue permeability, enabling the conversion of intravenous antibody therapies into SC formulations that improve patient convenience and reduce healthcare resource use. AstraZeneca gains exclusive rights to apply ALT‑B4 across multiple oncology antibodies worldwide.

Alteogen CEO Sun‑jae Park said the partnership with a leading global innovator validates the competitiveness of its technology and follows comprehensive technical and patent due diligence confirming ALT‑B4’s safety profile. He added that the collaboration will accelerate development of more convenient treatment options for patients.

This marks Alteogen’s sixth global licensing deal and builds on its 2020 agreement with Merck (MSD). The company continues to expand its patent portfolio to broaden the scope of its ALT‑B4 platform.